Literature DB >> 32991929

Adenoma-like adenocarcinoma: clinicopathologic characterization of a newly recognized subtype of colorectal carcinoma.

Iván A González1, Philip S Bauer2, Jingxia Liu3, Deyali Chatterjee4.   

Abstract

The 5th edition of the World Health Organization (WHO) Classification of Tumours (Digestive System) recognizes a new subtype of colorectal adenocarcinoma, called adenoma-like adenocarcinoma. In this study, we sought to determine its clinicopathologic associations and how it is comparable with adenocarcinoma, of no special type (NOS). We retrospectively reviewed all available archival slides of stage I-III colonic adenocarcinoma resection specimens at our institution from 2013 to 2016.Ninety-one cases were classified as adenoma-like adenocarcinoma, and 251 cases were classified as adenocarcinoma, NOS. Of the adenoma-like adenocarcinoma cases, a majority (65 cases, 71%) were composed exclusively of adenoma-like features, designated as pure adenoma-like adenocarcinoma, whereas in the rest, the component of adenoma-like morphology was more than 50% but less than 100%, designated as mixed adenoma-like adenocarcinoma. Compared with adenocarcinoma, NOS, adenoma-like adenocarcinoma cases were significantly associated with the absence of tumor budding (P < 0.001), the absence of an immature/myxoid desmoplastic reaction (P < 0.001), the presence of intraepithelial tumor-infiltrating lymphocytes (P = 0.006), involvement of fewer lymph nodes ( P < 0.001), fewer tumor deposits (P = 0.042), lower pT stage (P = 0.047), lower pN stage (P < 0.001), and consequently the pTNM prognostic group (P < 0.001), as well as better recurrence-free survival (RFS), as per univariate analysis than adenocarcinoma, NOS cases (P = 0.026) but not as per multivariate analysis. However, mixed adenoma-like adenocarcinoma had a worse RFS than pure adenoma-like adenocarcinoma (hazard ratio = 1.639, 95% confidence interval = 0.494-5.437). Our findings not only support the importance of distinguishing this new subtype of colorectal adenocarcinoma but also raise the question whether mixed adenoma-like adenocarcinoma cases should be included in this category, and if so, whether 50% is an appropriate cutoff, as currently defined by the WHO.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenoma-like adenocarcinoma; Colorectal adenocarcinoma; Colorectal cancer; Desmoplastic reaction; Intraepithelial tumor-associated lymphocytes; Tumor budding

Mesh:

Year:  2020        PMID: 32991929      PMCID: PMC8985589          DOI: 10.1016/j.humpath.2020.09.008

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  21 in total

1.  Desmoplastic Pattern at the Tumor Front Defines Poor-prognosis Subtypes of Colorectal Cancer.

Authors:  Hideki Ueno; Yukihide Kanemitsu; Shigeki Sekine; Megumi Ishiguro; Eisaku Ito; Yojiro Hashiguchi; Fukuo Kondo; Hideyuki Shimazaki; Satsuki Mochizuki; Yoshiki Kajiwara; Eiji Shinto; Junji Yamamoto
Journal:  Am J Surg Pathol       Date:  2017-11       Impact factor: 6.394

2.  Extent and Location of Tumor-Infiltrating Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome to Adjuvant Active Specific Immunotherapy.

Authors:  Annelies W Turksma; Veerle M H Coupé; Marc C Shamier; Kevin L H Lam; Vincent A de Weger; Jeroen A M Belien; Alfons J van den Eertwegh; Gerrit A Meijer; Chris J L M Meijer; Erik Hooijberg
Journal:  Clin Cancer Res       Date:  2015-09-29       Impact factor: 12.531

3.  Clinicopathological significance of the 'keloid-like' collagen and myxoid stroma in advanced rectal cancer.

Authors:  H Ueno; A Jones; J R Jass; I C Talbot
Journal:  Histopathology       Date:  2002-04       Impact factor: 5.087

4.  Tumor Budding in Colorectal Carcinoma: Confirmation of Prognostic Significance and Histologic Cutoff in a Population-based Cohort.

Authors:  Rondell P Graham; Robert A Vierkant; Lori S Tillmans; Alice H Wang; Peter W Laird; Daniel J Weisenberger; Charles F Lynch; Amy J French; Susan L Slager; Yassaman Raissian; Joaquin J Garcia; Sarah E Kerr; Hee Eun Lee; Stephen N Thibodeau; James R Cerhan; Paul J Limburg; Thomas C Smyrk
Journal:  Am J Surg Pathol       Date:  2015-10       Impact factor: 6.394

5.  Invasive papillary adenocarcinoma of the colon.

Authors:  Juan P Palazzo; Tina Bocker Edmonston; Linda M Chaille-Arnold; Susan Burkholder
Journal:  Hum Pathol       Date:  2002-03       Impact factor: 3.466

6.  Adenoma-like adenocarcinoma: a subtype of colorectal carcinoma with good prognosis, deceptive appearance on biopsy and frequent KRAS mutation.

Authors:  Raul S Gonzalez; Justin M M Cates; Mary Kay Washington; Robert Daniel Beauchamp; Robert J Coffey; Chanjuan Shi
Journal:  Histopathology       Date:  2015-06-04       Impact factor: 5.087

7.  Site-specific Differences in Colonic Adenocarcinoma: KRAS Mutations and High Tumor Budding Are More Frequent in Cecal Adenocarcinoma.

Authors:  Michael A Landau; Benjamin Zhu; Frances N Akwuole; Reetesh K Pai
Journal:  Am J Surg Pathol       Date:  2018-03       Impact factor: 6.394

8.  Clinicopathologic determinants of pathologic treatment response in neoadjuvant treated rectal adenocarcinoma.

Authors:  Iván González; Philip S Bauer; William C Chapman; Zahra Alipour; Rehan Rais; Jingxia Liu; Deyali Chatterjee
Journal:  Ann Diagn Pathol       Date:  2019-12-14       Impact factor: 2.090

9.  DNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma.

Authors:  Iván González; Bella Goyal; Michelle D Xia; Reetesh K Pai; Changqing Ma
Journal:  Hum Pathol       Date:  2018-10-28       Impact factor: 3.466

10.  The Prognostic Value of Tumor-Infiltrating lymphocytes in Stage II Colon Cancer. A Nationwide Population-Based Study.

Authors:  Ann C Eriksen; Flemming B Sørensen; Jan Lindebjerg; Henrik Hager; René dePont Christensen; Sanne Kjær-Frifeldt; Torben F Hansen
Journal:  Transl Oncol       Date:  2018-06-22       Impact factor: 4.243

View more
  1 in total

1.  Colorectal cancers with a residual adenoma component: Clinicopathologic features and KRAS mutation.

Authors:  Hyoun Wook Lee; Boram Song; Kyungneun Kim
Journal:  PLoS One       Date:  2022-09-09       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.